The pharmaceutical industry stands at a critical juncture, balancing the rapid pace of innovation in biologics and nanotechnology with the increasingly stringent demands for regulatory consistency and patient safety. To address these complex challenges, the American Association of Pharmaceutical Scientists (AAPS) and the United States Pharmacopeia (USP) have announced a major expansion of their collaborative efforts for the upcoming 2026 PharmSci 360 conference.
Scheduled for October 25–28, 2026, at the Ernest N. Morial Convention Center in New Orleans, the event is set to host a significant USP-led workshop, marking a departure from previous, more limited engagements. This expanded presence underscores a growing need for alignment between the scientific community’s cutting-edge development efforts and the foundational, enforceable standards that ensure global drug quality.
The Evolution of a Strategic Partnership
The collaboration between AAPS and USP has been a cornerstone of recent industry gatherings, yet the 2026 iteration represents a quantum leap in scope. In previous years, the USP’s footprint was primarily limited to exhibit-hall stage sessions and targeted technical talks. For example, during the 2023 meeting, the focus was centered on the nuances of excipient and raw material grading—a vital topic for supply chain integrity. By 2025, the presence had grown, but it remained decentralized.
The 2026 announcement signifies a transition toward a more integrated, educational, and interactive model. By hosting a comprehensive two-and-a-half-day workshop directly within the exhibit hall, the organizations are effectively bridging the gap between abstract scientific research and the practical, day-to-day enforcement of quality standards.
Key Areas of Focus
The workshop, running from October 26 to 28, will dissect four pillars of modern pharmaceutical development:
- Complex Generics: Navigating the regulatory and analytical complexities inherent in bringing non-traditional generic drugs to market.
- Excipient Quality: Establishing benchmarks for purity and performance in a globalized supply chain.
- Inhalation Standards: Addressing the unique challenges of lung-delivery systems and particle-size characterization.
- Novel Excipients: Evaluating the regulatory pathway for new delivery vehicles that do not yet have established USP-NF monographs.
These sessions are designed to clarify the compendial standards found in the USP–NF (United States Pharmacopeia and the National Formulary), which serve as the legal bedrock for FDA enforcement under the Federal Food, Drug, and Cosmetic Act.
Deep Integration: The Scientific Program
Beyond the dedicated workshop, USP staff are woven into the fabric of the main scientific program at PharmSci 360. This integration moves beyond simple attendance, with experts from the USP taking on roles as moderators and lead speakers, ensuring that quality and standards are discussed throughout the event’s various tracks.
Biologics and the Next Frontier
One of the most anticipated sessions occurs on Monday, featuring Diane McCarthy, Ph.D., vice president of global biologics at USP. Dr. McCarthy will lead a high-level discussion on the future of public standards for biologics development—a field currently grappling with rapid iteration and high manufacturing costs.
The symposium, moderated by Allison Radwick, Ph.D., senior regulatory and policy communications manager at USP, promises to be a lightning rod for innovation. It includes a powerhouse lineup of industry experts:
- Anurag Rathore, Ph.D. (IIT Delhi): Addressing the "holy grail" of manufacturing—whether next-generation platforms can realistically produce monoclonal antibodies at a cost of $10 per gram.
- Tongzhou Liu, Ph.D. (AbbVie): Offering critical insights into formulation choices during commercial manufacturing, where the margin for error is razor-thin.
- Luis Brito, Ph.D. (Moderna): Exploring the complexities of lipid nanoparticle development, a delivery technology that has become indispensable in the wake of mRNA vaccine success.
Keynotes and Predictive Development
The conference’s keynote sessions will also benefit from USP oversight. Ravi Kiran Kaja, Ph.D., a senior principal scientist at USP, will moderate two pivotal keynotes that highlight the industry’s shift toward predictive and scalable manufacturing:
- Alan Watts, Ph.D. (Catalent): Providing a case study on the scale-up of Inbrija, a critical look at moving a drug from clinical concepts to large-scale commercial reality.
- Shawn Zhang, Ph.D. (digiM Solution): Focusing on microstructure-based predictive development, a method that leverages advanced imaging and AI to reduce the need for iterative physical testing.
Perspectives on Industry Alignment
The expansion of the USP-AAPS partnership is not merely a logistical choice; it is a strategic response to a changing regulatory landscape. Catherine Sheehan, senior director of growth programs for excipients and foods at USP, noted that the alignment between the two organizations is mission-critical.
"USP and AAPS are aligned in our shared mission to help industry and regulators address evolving challenges in pharmaceutical quality," Sheehan stated. "This workshop will bring together a range of stakeholder perspectives to foster innovation, strengthen regulatory confidence, and ultimately help increase the availability of quality medicines for the patients who need them."
This sentiment reflects the broader goal of PharmSci 360: to create a cohesive environment where the "silos" of drug discovery, regulatory affairs, and manufacturing are dismantled. By bringing together the policymakers who set the standards and the scientists who must work within them, the conference aims to create a feedback loop that accelerates, rather than hinders, innovation.
Implications for the Future of Drug Development
The 2026 PharmSci 360 conference arrives at a time when the industry is facing significant pressure to increase efficiency while maintaining, or exceeding, current safety standards. The implications of this workshop-heavy format are far-reaching:
1. Regulatory Confidence
For smaller biotech firms and startups, the terminology and requirements surrounding USP-NF standards can be daunting. By providing a dedicated, multi-day workshop, the USP is lowering the barrier to entry for innovators who need to understand how to design their products to meet future regulatory requirements before they even reach the clinic.
2. The Rise of "Quality by Design"
The involvement of experts like Dr. Shawn Zhang highlights the industry’s pivot toward "Quality by Design" (QbD). By using predictive modeling and digital twins to anticipate how a drug will behave, manufacturers can build quality into the process from the start. This aligns perfectly with the USP’s mission to set standards that are not just reactive but anticipatory of new drug modalities.
3. Supply Chain Resilience
The emphasis on excipient quality is a direct response to the global supply chain disruptions seen over the last five years. By providing a forum to discuss raw material grades and the standardization of novel excipients, the USP is helping the industry build a more resilient infrastructure that can withstand global instability.
Navigating the 2026 Agenda
The AAPS PharmSci 360 program for 2026 is designed to be comprehensive, covering the entire lifecycle of a drug product. Beyond the USP-led sessions, the conference will span:
- Preclinical and Translational Sciences: Bridging the gap between animal models and human clinical outcomes.
- Formulation and Delivery: Exploring the next generation of drug delivery, including advanced oral, injectable, and inhalation technologies.
- Analytical Characterization and Bioanalytics: Providing the tools necessary to prove that a drug is exactly what it claims to be, at every stage of the manufacturing process.
For those attending in New Orleans, the USP’s booth (Booth 2931) will serve as a central hub for inquiries, complemented by a special poster collection that highlights the latest research in compendial standards.
As the pharmaceutical industry continues to push the boundaries of what is possible—from cell and gene therapies to complex mRNA-based delivery systems—the need for a robust, predictable, and transparent set of standards has never been higher. By fostering this collaborative dialogue at PharmSci 360, AAPS and USP are ensuring that the innovations of today become the high-quality, reliable medicines of tomorrow.
The stage is set for a landmark event in New Orleans, where the intersection of science and policy will define the next chapter of global health.
About the Author
